New treatment for cancer targeting cell respiration and mitochondrial function has been published

By Rhoda Wilson on November 25, 2024

In September, a paper was published in the Journal of Orthomolecular Medicine which describes the scientific rationale for the hybrid orthomolecular protocol as well as providing detailed information on the protocol itself.

The hybrid orthomolecular protocol is a new strategy for treating cancer. It involves the use of various supplements and dietary interventions, including vitamin D, zinc, ivermectin, benzimidazoles and DON, as well as a ketogenic diet and fasting.

First-in-the-world ivermectin, mebendazole and fenbendazole protocol in cancer has been peer-reviewed and published on 19 September 2024!

The future of cancer treatment starts NOW.

My thanks to lead authors Ilyes Baghli and Pierrick Martinez for their incredibly inspired work, FLCCC’s Dr. Paul Marik for his extensive work on repurposed drugs and every co-author who worked hard to bring this paper to life.

Table of Contents

The Mitochondrial-Stem Cell Connection and Current Cancer Therapies

Vitamin C and Cancer Treatment

Vitamin D and Cancer Treatment

Zinc and Cancer Treatment

Pharmaceutical Agents Targeting the MSCC

Ivermectin and Cancer Treatment

Benzimidazoles and Cancer Treatment

Diazo-5-oxo-L-norleucine (“DON”) and Cancer Treatment

Fasting, Ketogenic Diet and Cancer Treatment

Press-Pulse Therapy and Physical Activity

Hybrid Orthomolecular Protocol for Targeting the MSCC

more:

https://expose-news.com/2024/11/25/new-treatment-for-cancer-published/